The proprietary androgen, 7a-methyl-19-nortestosterone (MENT?) in combination with DMPA progestin is being investigated for male contraception. MENT is 10 fold more effective than testosterone (T) in suppressing gonadotropins and maintaining muscle mass. Therefore, it is possible to deliver a dose of MENT via silastic implants that will be effective in suppressing gonadotropins and spermatogenesis. In addition, MENT will have potential health benefits on prostate, bone and muscle mass and myelin regeneration based on the results of in vitro and animal studies. For example, (1) MENT is resistant to 5a-reduction, therefore, it is less stimulatory on the prostate at a comparable replacement dose;(2) MENT is aromatized to a potent estrogen, thereby, maintains sexual behavior in animals and men;(3) MENT does not bind to sex hormone binding globulin (SHBG) and has similar pharmacokinetics as T;and (4) MENT was recently shown to increase remyelination of neuronal cells (M. Schumacher, unpublished). Hence the long-term use of MENT in men is expected to be superior to T with added health benefits. First generation exogenous treatment regimens using testosterone injection, gel or biodegradable pellet or MENT acetate (MENT Ac) silastic implant showed limited efficacy in male contraceptive clinical trials. Second generation regimens using androgen in combination with a progestin such as levonorgestrel, etonogestrel or DMPA showed higher efficacy in suppressing spermatogenesis. In this research project, we will use a regimen of three MENT Ac implants (releasing ~ 1500 pg/day of MENT Ac) in combination with either a single DMPA injection at the start or multiple injections at 3 month intervals. MENT Ac implants will be manufactured, and the clinical trial will commence during the next funding cycle (pending approval). In addition, pharmacological and mechanistic studies will be conducted to determine the safety and health benefits of MENT and DMPA use. MENT Ac is an acetylated derivative of MENT and is used in implant manufacturing for optimal release rates. MENT and MENT Ac are used interchangeably since MENT Ac released from implants is rapidly hydrolyzed to the active MENT. Depo Provera (DMPA, Pfizer) injectable is an approved female contraceptive and is being investigated for male contraception. Depo provera releases an active progestin, medroxyprogesterone acetate (MPA). MPA will be used in animal and in vitro studies.

Public Health Relevance

; Even though, women have several contraceptive choices, nearly half of them will discontinue use for various reasons. Surveys have indicated that men are willing to participate in contraceptive clinical trials and will use them if safe and effective methods are available. Development of a hormonal male contraceptive method based on MENT Ac implants in combination with DMPA injectable formulation will be particularly relevant for couples to control unintended pregnancy.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
2U54HD029990-21
Application #
8400526
Study Section
Special Emphasis Panel (ZHD1)
Project Start
Project End
Budget Start
2011-03-01
Budget End
2012-02-29
Support Year
21
Fiscal Year
2012
Total Cost
$202,664
Indirect Cost
Name
Population Council
Department
Type
DUNS #
071050090
City
New York
State
NY
Country
United States
Zip Code
10017
Li, Linxi; Tang, Elizabeth I; Chen, Haiqi et al. (2017) Sperm Release at Spermiation Is Regulated by Changes in the Organization of Actin- and Microtubule-Based Cytoskeletons at the Apical Ectoplasmic Specialization-A Study Using the Adjudin Model. Endocrinology 158:4300-4316
Tung, Kenneth S K; Harakal, Jessica; Qiao, Hui et al. (2017) Egress of sperm autoantigen from seminiferous tubules maintains systemic tolerance. J Clin Invest 127:1046-1060
Gao, Ying; Chen, Haiqi; Lui, Wing-Yee et al. (2017) Basement Membrane Laminin ?2 Regulation of BTB Dynamics via Its Effects on F-Actin and Microtubule Cytoskeletons Is Mediated Through mTORC1 Signaling. Endocrinology 158:963-978
Chen, Haiqi; Li, Michelle W M; Yan Cheng, C (2017) Drebrin and Spermatogenesis. Adv Exp Med Biol 1006:291-312
Gao, Ying; Chen, Haiqi; Xiao, Xiang et al. (2017) Perfluorooctanesulfonate (PFOS)-induced Sertoli cell injury through a disruption of F-actin and microtubule organization is mediated by Akt1/2. Sci Rep 7:1110
Jesus, Tito T; Oliveira, Pedro F; Sousa, Mário et al. (2017) Mammalian target of rapamycin (mTOR): a central regulator of male fertility? Crit Rev Biochem Mol Biol 52:235-253
Kumar, Narender; Fagart, Jerôme; Liere, Philippe et al. (2017) Nestorone® as a Novel Progestin for Nonoral Contraception: Structure-Activity Relationships and Brain Metabolism Studies. Endocrinology 158:170-182
Gao, Ying; Mruk, Dolores; Chen, Haiqi et al. (2017) Regulation of the blood-testis barrier by a local axis in the testis: role of laminin ?2 in the basement membrane. FASEB J 31:584-597
Chen, Haiqi; Mruk, Dolores D; Lee, Will M et al. (2017) Regulation of spermatogenesis by a local functional axis in the testis: role of the basement membrane-derived noncollagenous 1 domain peptide. FASEB J 31:3587-3607
Oliveira, Pedro F; Cheng, C Y; Alves, Marco G (2017) Emerging Role for Mammalian Target of Rapamycin in Male Fertility. Trends Endocrinol Metab 28:165-167

Showing the most recent 10 out of 243 publications